Q-omics provides the consensus-scored KRTAP16-1 profile across patient tissues and cancer cell-line models. KRTAP16-1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, KRTAP16-1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, KRTAP16-1 RNA expression shows 7,077 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCS, KIRC, and LIHC as cancer lineages where KRTAP16-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP16-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP16-1 survival associations across molecular data types. KRTAP16-1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP16-1 RNA expression–survival associations across cancer types. High KRTAP16-1 expression shows unfavorable associations in KICH and PCPG, but favorable associations in UCS, PAAD, HNSC and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for KRTAP16-1 RNA expression.
This table summarizes KRTAP16-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP16-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP16-1 shows lower tumor expression in BRCA, PAAD and KICH and higher tumor expression in KIRC, LUSC and KIRP. The KIRC box plot shows higher KRTAP16-1 RNA expression in tumor versus normal tissue (log2 FC = +0.052, t-test p < 0.001).
This table shows molecular features associated with KRTAP16-1 in patient tissues and cancer cell lines. In patient samples, KRTAP16-1 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP16-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
